The cell sheet gene therapy market is seeing leading players supported by regulatory bodies and the progressive environment of Japan.
1 report, 1 independent
Updated Aug 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The cell sheet gene therapy market is seeing leading players supported by regulatory bodies and the progressive environment of Japan.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Abeona Therapeutics
biopharmaceutical company
Nothing else this week.
- FDA
Related events
- FDA placed a clinical hold on a gene therapy involving Hunter.
- The FDA reviewed gene therapy applications and provided milestone payments for dosing involving Regenxbio and AbbVie.
- FDA raised concerns over cell therapy evidence for Capricor Therapeutics, causing a sharp drop in stock price.
- Solid Biosciences received FDA approval for a gene therapy trial on July 9, 2025.
- uniQure N.V. traded on the Nasdaq stock exchange and submitted a Biologics License Application (BLA) for accelerated approval of its gene therapy.
Coverage
Newest first; wire copies grouped- GlobeNewswireCell Sheet-based Gene Therapy Market Analysis and Forecast, 2025-2035 | Abeona Therapeutics, CellSeed, J-TEC, and Holostem Lead with First-in-Class Therapies and Strong Commercialization Strategies T